Last reviewed · How we verify
measles-rubella vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against measles and rubella viruses by introducing attenuated (weakened) forms of both viruses.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against measles and rubella viruses by introducing attenuated (weakened) forms of both viruses. Used for Prevention of measles, Prevention of rubella.
At a glance
| Generic name | measles-rubella vaccine |
|---|---|
| Also known as | measles-rubella live attenuated vaccine, Measles-Rubella Virus Vaccine Live US Pharmacopeia (USP) |
| Sponsor | Sichuan Center for Disease Control and Prevention |
| Drug class | Live attenuated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The measles-rubella vaccine contains live attenuated strains of measles and rubella viruses that replicate in vaccinated individuals without causing disease. This triggers both humoral (antibody) and cell-mediated immune responses, providing protective immunity against natural infection with these viruses. The vaccine prevents systemic viral replication and the characteristic rash and complications associated with measles and rubella infection.
Approved indications
- Prevention of measles
- Prevention of rubella
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Rash
- Arthralgia or arthritis
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age (PHASE3)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- measles-rubella vaccine CI brief — competitive landscape report
- measles-rubella vaccine updates RSS · CI watch RSS
- Sichuan Center for Disease Control and Prevention portfolio CI